G

Genexine Inc
KOSDAQ:095700

Watchlist Manager
Genexine Inc
KOSDAQ:095700
Watchlist
Price: 4 595 KRW 7.36% Market Closed
Market Cap: ₩209.3B

Operating Margin

-714.7%
Current
Improving
by 480.2%
vs 3-y average of -1 194.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-714.7%
=
Operating Income
₩-31B
/
Revenue
₩4.3B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-714.7%
=
Operating Income
₩-31B
/
Revenue
₩4.3B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
Genexine Inc
KOSDAQ:095700
209B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 99% of companies in Korea
Percentile
1st
Based on 2 615 companies
1st percentile
-714.7%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

Genexine Inc
Glance View

Market Cap
209.3B KRW
Industry
Biotechnology

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Intrinsic Value
1 202.9 KRW
Overvaluation 74%
Intrinsic Value
Price
G
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-714.7%
=
Operating Income
₩-31B
/
Revenue
₩4.3B
What is Genexine Inc's current Operating Margin?

The current Operating Margin for Genexine Inc is -714.7%, which is above its 3-year median of -1 194.9%.

How has Operating Margin changed over time?

Over the last 3 years, Genexine Inc’s Operating Margin has decreased from -354.9% to -714.7%. During this period, it reached a low of -2 805.5% on Mar 31, 2025 and a high of -354.9% on Aug 30, 2022.

Back to Top